Revolution Medicines Inc (RVMDW)
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
Volaris Reports April 2026 Traffic Results: Load Factor of 85%
Gates Industrial to Participate in the 19th Annual Wolfe Research Global Transportation & Industrials Conference
Inspired Entertainment Extends Long-Term Agreement with Paddy Power for Gaming Terminals and Content
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
Magnera Reports Second Quarter Results
Autoliv Declares Quarterly Dividend USA - English USA - English
B2Gold Reports Q1 2026 Results
Autoliv Declares Quarterly Dividend
BuzzFeed, Inc. First Quarter 2026 Financial Results Release Rescheduled to Monday, May 11, 2026